With its lead CAR-T flash­ing some PhI da­ta, Ar­cel­lx read­ies a jump to Nas­daq

Near­ly a year af­ter un­veil­ing a megaround Se­ries C, Ar­cel­lx is head­ed to­ward Nas­daq.

The Gaithers­burg, MD-based biotech pen­ciled in a $100 mil­lion IPO raise last Fri­day, aim­ing to take its clas­sic CAR-T ther­a­py and ex­per­i­men­tal, con­trol­lable CAR-T to the pub­lic mar­ket. The lead pro­gram, a clas­si­cal CAR-T which gar­nered the ex­cite­ment for last April’s hefty $115 mil­lion raise, will like­ly head to a Phase II study with the IPO funds, Ar­cel­lx not­ed in its S-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER